Crassula Pharmaceuticals Launches India’s First QuanticSphere Drug-Delivery Technology

Crassula Pharmaceuticals has officially launched its proprietary QuanticSphere drug-delivery technology in India, marking a significant milestone in the advancement of pharmaceutical and nutraceutical delivery systems. The launch event, held in Indore, represents the first introduction of QuanticSphere in the Indian market and underscores Crassula’s continued focus on science-driven innovation and patient-centric formulation design.

QuanticSphere is a patented delivery platform engineered to enhance the absorption, stability, and bioavailability of active pharmaceutical ingredients and nutritional compounds. The technology utilizes nano-scale, phospholipid-based vesicles to protect active ingredients from degradation in the digestive tract while facilitating efficient systemic delivery.

Addressing Limitations of Conventional Oral Formulations

One of the longstanding challenges in oral drug and nutrient delivery is poor absorption, which can limit therapeutic effectiveness and require higher dosing. QuanticSphere is designed to address this limitation by improving ingredient transport across biological membranes, maintaining stability in the gastrointestinal environment, and supporting sustained availability in the body.

The platform has broad relevance across multiple therapeutic and wellness categories, including joint health, musculoskeletal support, cartilage integrity, post-menopausal health, and general nutritional supplementation. Its design prioritizes patient tolerability, digestive comfort, and long-term compliance.

Expert Insights Shared at the Launch

During the launch event, scientific and medical experts discussed the clinical and technical significance of the QuanticSphere platform.

Dr. Bhavana Gupta, Chief Technical Officer of Crassula Pharmaceuticals, highlighted the system’s design and performance:

“QuanticSphere is a state-of-the-art delivery system developed by Crassula Pharmaceuticals. By encapsulating active ingredients in nano-sized, phospholipid-based vesicles, the technology enhances delivery efficiency while maintaining long-term stability and patient safety.”

Orthopedic specialists attending the event emphasized the potential relevance of the technology for joint-related formulations, noting its applicability in both current therapeutic approaches and future research initiatives.

Dr. Laveleen Gupta, Chief Scientific Officer of Crassula Pharmaceuticals, addressed the broader scope of the platform:

“QuanticSphere is designed as a versatile delivery platform. Beyond nutritional and joint-health applications, ongoing research is exploring its potential role in advanced therapeutic areas and chronic disease management.”

A Platform for Future Innovation

QuanticSphere has been developed as a modular and scalable technology capable of supporting a wide range of active compounds, including vitamins, minerals, botanical extracts, and pharmaceutical agents. Crassula Pharmaceuticals plans to expand its application across multiple product lines while continuing research and development efforts to explore additional therapeutic opportunities.

With this launch, Crassula Pharmaceuticals strengthens its position as a technology-driven healthcare organization focused on advancing delivery science and improving patient outcomes through innovation, precision, and clinical relevance.

Publisher Information

Crassula Pharmaceuticals

Innovating advanced drug-delivery technologies for pharmaceutical and nutraceutical applications.

For more information, visit: https://crassulapharma.com/contact